⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986435 | 0.64 | — | — | |
| SCHEMBL3945196 | 0.61 | — | — | |
| SCHEMBL12477767 | 0.60 | — | — | |
| SCHEMBL1620011 | 0.60 | — | — | |
| SCHEMBL4624675 | 0.59 | — | — | |
| SCHEMBL18934531 | 0.59 | — | — | |
| SCHEMBL52084 | 0.59 | — | — | |
| SCHEMBL16127877 | 0.58 | — | — | |
| SCHEMBL9737504 | 0.58 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL4444192 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-11925690-B2 | Bifunctional molecules for targeting Rpn11 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-12 | — | — | US | disclosed |
| CN-110612294-B | Human cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230082997-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| CN-100522972-C | Fused heterocyclic isoxazoline derivatives and their use as anti-depressants | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-05 | — | — | CN | disclosed |
| US-7501418-B2 | e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501418-B2 | e.g. 3-[4-(2-Methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-dicyclopenta[a,g]naphthalene; serotonine (5-HT) reuptake inhibitor, alpha 2-adrenoceptor antagonist; antidepressant, anxiolytic agent; Parkinson's disease, eating disorders, psychosis, obesity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-10 | — | — | US | disclosed |
| US-20060116378-A1 | Fused heterocyclic isoxazoline derivatives and their use as anti-derpressants | JANSSEN-CILAG S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| US-20060116378-A1 | Fused heterocyclic isoxazoline derivatives and their use as anti-derpressants | JANSSEN-CILAG S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| CN-1675224-A | fused heterocyclic isoxazoline derivatives and their use as antidepressants | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1554286-A1 | FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1554286-A1 | FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004018483-A1 | FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018483-A1 | FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-04 | — | — | WO | disclosed |